Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study
2024 · The Lancet · 58 citations
https://doi.org/10.1016/s0140-6736(24)00814-6
D
Debbie Robbrecht
Erasmus MC(NL)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
163
Papers
700
Citations
15
h-index
22
i10-index
Debbie Robbrecht is an academic researcher from Erasmus MC. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Bladder and Urothelial Cancer Treatments & Radiopharmaceutical Chemistry and Applications. The author has an h-index of 15, co-authored 139 publications.
ORCID: 0000-0003-2490-9991Papers by this author
worksBexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: The phase I/II first-in-human MATINS trial
2023 · Cell Reports Medicine · 25 citations
https://doi.org/10.1016/j.xcrm.2023.101307
Early dose escalation of LAVA-1207, a novel bispecific gamma-delta T-cell engager (Gammabody), in patients with metastatic castration-resistant prostate cancer (mCRPC).
2023 · Journal of Clinical Oncology · 17 citations
https://doi.org/10.1200/jco.2023.41.6_suppl.153
Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study
2025 · Journal of Clinical Oncology · 15 citations
https://doi.org/10.1200/jco-25-00678
Impact of progression at baseline and on-treatment progression events in three large prostate cancer trials
2019 · European Journal of Cancer · 10 citations
https://doi.org/10.1016/j.ejca.2019.10.029
Phase I/II trial of LAVA-1207, a novel bispecific gamma-delta T-cell engager alone, or with low dose IL-2 or pembrolizumab, in metastatic castration resistant prostate cancer (mCRPC).
2024 · Journal of Clinical Oncology · 7 citations
https://doi.org/10.1200/jco.2024.42.16_suppl.tps2672
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat